Get to know our clinical trials

Ensayo clínico para investigar la eficacia y la seguridad del domatinostat en combinación con avelumab en pacientes con carcinoma de células de Merkel metastásico no tratado. Inmunoterapia.

THIS CLINICAL STUDY WILL TEST THE SAFETY, TOLERABILITY AND CLINICAL EFFICACY OF DOMATINOSTAT IN COMBINATION WITH AVELUMAB. IT IS EXPECTED THAT PATIENTS WITH METASTATIC MERKEL CELL CARCINOMA CAN BE TREATED MORE EFFECTIVELY.

Status
In recruitment

Technical Summary

  • A PHASE II OPEN-LABEL MULTICENTER STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF DOMATINOSTAT IN COMBINATION WITH AVELUMAB IN PATIENTS WITH UNTREATED METASTATIC MERKEL CELL CARCINOMA - THE MERKLIN 1 STUDY - IMMUNOTHERAPY.
  • Code EudraCT: 2019-003575-19
  • Protocol number: 4SC-202-4-2019
  • Promoter: 4SC AG
  • Link to Clinical Trials

* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.

Do you want to participate in this trial?

Request an appointment for our specialists to assess whether you qualify for this clinical trial


Do you prefer to send us your reports?

If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.